论文部分内容阅读
目的 通过检测系统性红斑狼疮 (SLE)患者外周血单个核细胞 (PBMC)分泌细胞因子白细胞介素 10 (IL 10 )、干扰素 γ (IFN γ)水平 ,探讨T淋巴细胞亚群与SLE发病关系。方法 采用酶联免疫吸附法 (ELISA)测定 30例SLE患者和 10名健康志愿者PBMC培养上清IL 10和IFN γ水平。结果 ①SLE活动组PBMC自发分泌IL 10水平明显升高 ,与非活动组、对照组比较差异有显著性 (P <0 0 0 1) ;非活动组明显高于对照组 (P <0 0 1)。②PBMC分泌IFN γ水平三组 (SLE活动组、非活动组和对照组 )比较差异无显著性 (P >0 0 5 )。结论 IL 10、IFN γ作为区分CD4T细胞亚群的指标之一 ,间接反映了Th1、Th2细胞活化状态。本文研究结果显示 ,SLE患者PBMC分泌IL 10水平明显增高 ,且增高程度与病情活动性相关 ,IFN γ分泌水平无明显变化。提出Th2型细胞因子介导的免疫应答在SLE的发病机制中占主导地位 ,即“Th2优势应答”。我们认为PBMC分泌IL 10水平对SLE诊断和病情活动性监测均有一定临床意义。寻找有效方法调节SLE患者体内IL 10水平 ,从而调节Th1/Th2平衡 ,将为治疗SLE开辟一条新途径。
Objective To detect the levels of IL-10 and IFN-γ secreted by peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) and to explore the relationship between T lymphocyte subsets and SLE . Methods The levels of IL-10 and IFN-γ in supernatant of PBMC from 30 SLE patients and 10 healthy volunteers were determined by enzyme-linked immunosorbent assay (ELISA). Results ① The level of IL-10 secreted by PBMC in the SLE group was significantly higher than that in the inactive group and the control group (P <0.01), and significantly higher in the inactive group than in the control group (P <0.01) . ② The levels of IFNγ secreted by PBMC in three groups (SLE active group, inactive group and control group) showed no significant difference (P> 0.05). Conclusion IL-10 and IFN-γ, as one of the indicators to distinguish CD4 T cell subsets, indirectly reflect the activation status of Th1 and Th2 cells. The results of this study showed that IL-10 levels in peripheral blood mononuclear cells were significantly increased in SLE patients, and the level of IL-10 secretion was correlated with the activity of the disease, with no significant change in the level of IFN-γ secretion. The Th2-type cytokine-mediated immune response is proposed to dominate the pathogenesis of SLE, the “Th2 predominant response.” We believe that the level of IL-10 secreted by PBMC is of clinical significance for SLE diagnosis and monitoring of disease activity. Looking for an effective method to regulate the level of IL-10 in SLE patients so as to regulate Th1 / Th2 balance will open up a new way for the treatment of SLE.